UNITED STATES SECURITIES AND EXCHANGE COMMISSION MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2142067 (State or other jurisdiction of incorporation or organization) WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40908 MiNK Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or ...

Financial Data and Key Metrics Changes - The net loss for Q4 2022 was $7.8 million or $0.23 per share, compared to a net loss of $5.8 million or $0.18 per share in Q4 2021 [9] - The net loss for the full year 2022 was $28.0 million or $0.83 per share, an improvement from a net loss of $30.2 million or $1.16 per share in 2021 [9] - Cash balance at the end of Q4 2022 was $19.6 million, down from $38.9 million at the end of Q4 2021 [41] Business Line Data and Key Metrics Changes - The company has made significant advancements in its clinical programs, particularly with its lead product, agenT-797, which has shown a 70% survival rate in patients with viral ARDS, compared to control rates of 10% to 22% [4] - MiNK-215, an armored IL-15-FAP-CAR-iNKT, is in IND-enabling studies with submission planned for 2024 [7] Market Data and Key Metrics Changes - The company is focusing on expanding its data sets and indications for solid tumor cancers, particularly non-small cell lung cancer and relapsed refractory gastric cancer, where there are limited treatment options for patients [43] - The company is exploring opportunities in acute infections and respiratory distress, indicating a potential for external financing to support development in these areas [31] Company Strategy and Development Direction - The company aims to deepen its understanding of iNKT cells and their mechanisms, focusing on solid tumor cancers where iNKT therapies can complement existing treatments [40] - Strategic collaborations are a core part of the company's strategy to leverage its platforms and products effectively [61] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the advancements in cell therapy and the potential for iNKT cells to address significant unmet medical needs in oncology and beyond [35] - The company is committed to fiscal responsibility and is actively seeking partnerships to enhance its development capabilities [61] Other Important Information - The company has invested in high-throughput manufacturing technology, allowing for rapid production of iNKT cells, which enhances scalability and accessibility for patients [37] - iNKT cells have shown promise in treating viral infections, which could expand the application of cell therapies beyond oncology [58] Q&A Session Summary Question: Expansion cohort for gastric cancer - Management indicated that gastric cancer is one of the initial indications being evaluated, with plans for further exploration based on data presented at AACR [10][11] Question: Data expectations for AACR update - The company completed accrual for a Phase I solid tumor study and will present as much data as possible from that cohort at AACR [45][67] Question: Combination therapies with Botensilimab - Management discussed the potential for combining iNKT cells with Botensilimab, highlighting preclinical data showing enhanced efficacy in solid tumors [18][49] Question: Safety of allogeneic versus autologous iNKT therapies - Management clarified that their approach does not require lymphodepletion, which differentiates their product from others that have faced safety challenges [73] Question: Timelines for MiNK-413 - MiNK-413 is expected to be ready for IND enablement in 2024, with ongoing discussions about its development [66]

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2022 Earnings Conference Call November 2, 2022 ET Company Participants Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Jack Allen - Baird Operator Good morning, and welcome to MiNK Therapeutics' Third Quarter 2022 Conference Call and Webcast. All participants will be in a listen-only mode until the question-and-answer session. Please note ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR (Exact Name of Registrant as Specified in its Charter) Delaware 82-2142067 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdic ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2022 Earnings Conference Call August 9, 2022 11:00 AM ET Company Participants Kimberly Ha - Head of Investor Relations Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Kalpit Patel - B. Riley Securities Jack Allen - Baird Matthew Phipps - William Blair Operator Good day, and welcome to the MiNK Therapeutics Second Quarter 2022 Earnings Conference Call. Please note, today ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | Delaware | 82-2142067 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 149 Fifth Avenue | | | Suite 500 | | | New York, NY | 10010 | | (Address of principal executive offices) | (Zip Code) | | Registrant's telephone number, including area code: 212- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jur ...